Macular pigment lutein is antiinflammatory in preventing choroidal neovascularization. - Wikidata - awgldk - TriplyDB

Macular pigment lutein is antiinflammatory in preventing choroidal neovascularization.

Macular pigment lutein is antiinflammatory in preventing choroidal neovascularization.

http://www.wikidata.org/entity/Q33302396

about

Lutein and zeaxanthin for reducing morbidity and mortality in preterm infants Management of Ocular Diseases Using Lutein and Zeaxanthin: What Have We Learned from Experimental Animal Studies?Suppression of experimental choroidal neovascularization by curcumin in mice Influence of age on retinochoroidal healing processes after argon photocoagulation in C57bl/6j mice.Lipid and protein oxidation in newborn infants after lutein administration.Roles of NFκB-miR-29s-MMP-2 circuitry in experimental choroidal neovascularization.Neurodegenerative influence of oxidative stress in the retina of a murine model of diabetes.Monocyte/macrophages promote vasculogenesis in choroidal neovascularization in mice by stimulating SDF-1 expression in RPE cells.Neuroprotective response after photodynamic therapy: role of vascular endothelial growth factor Suppression and regression of choroidal neovascularization in mice by a novel CCR2 antagonist, INCB3344 Lutein and zeaxanthin intake and the risk of age-related macular degeneration: a systematic review and meta-analysis.Neuroprotective effects of lutein in the retina The effect of lutein- and zeaxanthin-rich foods v. supplements on macular pigment level and serological markers of endothelial activation, inflammation and oxidation: pilot studies in healthy volunteers.The effect of lutein supplementation on blood plasma levels of complement factor D, C5a and C3d.The effect of modified eggs and an egg-yolk based beverage on serum lutein and zeaxanthin concentrations and macular pigment optical density: results from a randomized trial.The relation between serum lipids and lutein and zeaxanthin in the serum and retina: results from cross-sectional, case-control and case study designs Lutein Leads to a Decrease of Factor D Secretion by Cultured Mature Human Adipocytes.Joint Associations of Diet, Lifestyle, and Genes with Age-Related Macular Degeneration.Radical scavenging activity-based and AP-1-targeted anti-inflammatory effects of lutein in macrophage-like and skin keratinocytic cells.Overall diet quality and age-related macular degeneration.The role of lutein in eye-related disease IL10-driven STAT3 signalling in senescent macrophages promotes pathological eye angiogenesis.Lutein acts via multiple antioxidant pathways in the photo-stressed retina.Role of antioxidant enzymes and small molecular weight antioxidants in the pathogenesis of age-related macular degeneration (AMD)The Association between the Lipids Levels in Blood and Risk of Age-Related Macular Degeneration.Parahippocampal Cortex Mediates the Relationship between Lutein and Crystallized Intelligence in Healthy, Older Adults.Genetic evidence for role of carotenoids in age-related macular degeneration in the Carotenoids in Age-Related Eye Disease Study (CAREDS).Carotenoids.Effect of Carotenoid Supplemented Formula on Carotenoid Bioaccumulation in Tissues of Infant Rhesus Macaques: A Pilot Study Focused on Lutein.Cholesterol crystals induce inflammatory cytokines expression in a human retinal pigment epithelium cell line by activating the NF-κB pathway.Special features of human retinal angiogenesis.Microalgal carotenoids: beneficial effects and potential in human health.Mitochondrial DNA has a pro-inflammatory role in AMD.Lutein and Zeaxanthin Isomers in Eye Health and Disease.Antioxidant effect of lutein towards phospholipid hydroperoxidation in human erythrocytes.Effect of lutein and antioxidant supplementation on VEGF expression, MMP-2 activity, and ultrastructural alterations in apolipoprotein E-deficient mouse.Beneficial effect of docosahexanoic acid and lutein on retinal structural, metabolic, and functional abnormalities in diabetic rats.Effect of zeaxanthin and antioxidant supplementation on vascular endothelial growth factor (VEGF) expression in apolipoprotein-E deficient mice.Changes in macular pigment optical density and serum concentrations of lutein and zeaxanthin in response to weight loss.Pharmacokinetic properties of lutein emulsion after oral administration to rats and effect of food intake on plasma concentration of lutein.

P2860

Q24185832-8C93F49D-6D68-4826-91E4-FFE831AF3BD6 Q26776069-8ED6FD2C-CF26-4279-8585-978242921399 Q28484654-03274B21-CCC8-47FF-B49E-489A4D944EF8 Q33426876-A713177B-BFA3-4E96-B73E-50D25590C0B5 Q33614323-8FF412B2-1A7D-4D8E-8DE1-F27BFD675FCF Q33647292-CAB8BDAD-A77F-45C4-B757-4EAEE1FDC049 Q33773287-B8F6539E-216A-4E2E-80E5-4C49D33B212A Q33927575-04510EDF-4B50-4379-A83F-E7290949BFB3 Q34101883-8EFAB1AD-03B8-4D68-8724-07F748E0D975 Q34113663-1A95D43A-4528-48FF-95CF-E38B3764E66D Q34214289-B5658678-C534-45AF-A0D8-1840FDDB760F Q34634743-5D1326C1-B9E0-4568-ABE0-B07A78B11F4C Q34635706-5FE9E061-3414-44B1-A54C-DE094B934641 Q34979785-0A57568F-34F6-4D92-8C72-D8CF2466685D Q35133394-6FBB82FF-714D-4D22-8AD0-83F958C9C7EA Q35847931-CFCB631A-CE23-4262-8F24-A62E28EBA428 Q36173190-79BEEA65-BF03-41E4-BAD0-186FB9D5F4A2 Q36468066-36DEB565-1B93-4312-934D-37FA6BFA9D6B Q36711851-F205993D-99E8-4EDF-A485-A3A674120D7B Q36936663-A44CB633-F08C-412B-88D4-C0017FCEFD97 Q37002600-282EF531-DF9C-46EC-B9DD-91247F265659 Q37031844-1C7E47EB-16FC-4B96-A6CE-3355F367B432 Q37117609-90B6EA57-2D10-429E-BD1B-8BEABD726BB3 Q37298565-6DE45CF7-48EC-4767-9B1B-FA390FCAEE65 Q37374027-35B386B5-C78A-4D3B-9A7B-A26C90F82CDC Q37474988-B437F19E-A5AA-40ED-97F5-D8929C9B636D Q37537304-DE480867-5085-4876-BA6C-8F034E8E2944 Q37616210-EA3F8262-9440-43C6-8C3A-45594850222A Q37628418-45FA0042-E7B3-4C38-9492-E4817ACC80E5 Q37671584-1C365159-90FD-48F9-9E0A-E5E93C80F223 Q37675923-C73808DE-4EDE-464E-9C69-776CE56315C0 Q38183609-E3A74239-4B63-42BC-AB94-5DF856C2094C Q38841002-35D1306F-373B-4A4F-BE81-0016D5C5CECF Q38901504-CBA3271E-DB44-4614-8992-FFDA6A78B39B Q39961555-F41CDD20-D555-419A-A2AF-4C716C18A76D Q40812272-4F928D3D-1B1F-43E7-8E73-7D80A7073B7D Q43230861-D9A84BBB-13E8-4F6B-9A80-025D1C03F47B Q43245703-9AE36772-3FBC-4AF8-B4B5-610F6C0ECDFD Q47401647-43277A68-2140-4A11-BE2C-E402AE4BC0D0 Q50526715-F1CDEC2D-D0BF-40F7-ABB0-63F972669BBE

P2860

Macular pigment lutein is antiinflammatory in preventing choroidal neovascularization.

http://www.wikidata.org/entity/Q33302396

description

2007 nî lūn-bûn

@nan

2007 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Macular pigment lutein is antiinflammatory in preventing choroidal neovascularization.

@ast

Macular pigment lutein is antiinflammatory in preventing choroidal neovascularization.

@en

Macular pigment lutein is antiinflammatory in preventing choroidal neovascularization.

@nl

type

label

Macular pigment lutein is antiinflammatory in preventing choroidal neovascularization.

@ast

Macular pigment lutein is antiinflammatory in preventing choroidal neovascularization.

@en

Macular pigment lutein is antiinflammatory in preventing choroidal neovascularization.

@nl

prefLabel

Macular pigment lutein is antiinflammatory in preventing choroidal neovascularization.

@ast

Macular pigment lutein is antiinflammatory in preventing choroidal neovascularization.

@en

Macular pigment lutein is antiinflammatory in preventing choroidal neovascularization.

@nl

P1433

Q33302396-0F67CFDF-464D-4EBB-806A-D9135A0FB7F6

P1476

Q33302396-1D1CDF08-7139-4D94-BA79-16763114DCC3

P2093

Q33302396-3BB1D29D-A4CC-419D-B6A6-D79E7FBFD5F3

Q33302396-4C8B532E-29E9-4C24-96F1-020545D456DC

Q33302396-6EA82CC5-B26B-4F46-90CB-79DBD1D7534E

Q33302396-77AD7DD4-0644-498A-8033-323F40DAF599

Q33302396-8393B8B5-FBD6-4857-9DBB-E52C719AF4A6

Q33302396-86F0601C-CACA-4518-B770-6F5BE6720ECF

Q33302396-881A1495-0246-41D7-894C-A6E54C9A4A84

Q33302396-9A77EE7B-CF62-4071-84FC-648C33533613

Q33302396-9F8D8127-D72E-4314-8756-2C7FF79FB45F

Q33302396-BBFF3A5C-65E1-4DF4-B3C5-E73B8980D562

P304

Q33302396-6533B64D-2928-4283-9FC7-56357685F9EF

P31

Q33302396-A160F950-68D3-4777-B73E-E7D2E45DD2B4

P356

Q33302396-2BFCFA75-14D2-4A8D-A080-1AF923CF7FF5

P407

Q33302396-635CEF03-718E-4248-B8B8-132C58EA569B

P433

Q33302396-F4D7AE47-0FC6-4761-93F7-4B219CF1EF8C

P478

Q33302396-5FA5794A-4E78-46AD-8910-3D7F4CF78499

P577

Q33302396-F3B1985F-79D7-4C7D-80EE-7E894DDE7C97

P5875

Q33302396-9FCAE632-39C2-469A-9FB7-A99842F319B5

P698

Q33302396-08235C29-A34E-42F5-8558-7AEFB45FF243

P921

Q33302396-52B259CE-52D9-48AE-A971-D21A5AFA97F8

P356

ATVBAHA.107.151431

P1433

Arteriosclerosis, Thrombosis, and Vascular Biology

P1476

Macular pigment lutein is antiinflammatory in preventing choroidal neovascularization.

@en

P2093

Kanako Izumi-Nagai

http://www.w3.org/2001/XMLSchema#string

Kazuhiro Ohgami

http://www.w3.org/2001/XMLSchema#string

Kazuo Tsubota

http://www.w3.org/2001/XMLSchema#string

Kazuo Umezawa

http://www.w3.org/2001/XMLSchema#string

Norihiro Nagai

http://www.w3.org/2001/XMLSchema#string

Shigeaki Ohno

http://www.w3.org/2001/XMLSchema#string

Shingo Satofuka

http://www.w3.org/2001/XMLSchema#string

Susumu Ishida

http://www.w3.org/2001/XMLSchema#string

Yoko Ozawa

http://www.w3.org/2001/XMLSchema#string

Yuichi Oike

http://www.w3.org/2001/XMLSchema#string

P304

2555-2562

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/ATVBAHA.107.151431

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P577

2007-10-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5913528

http://www.w3.org/2001/XMLSchema#string

P698

17932319

http://www.w3.org/2001/XMLSchema#string

P921

neovascularization